Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
MAIA BIOTECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
|
|
Security Type |
|
Security Class Title |
|
Fee Calculation or Carry Forward Rule |
|
Amount Registered |
|
|
Proposed Maximum Offering Price Per Unit |
|
|
Maximum Aggregate Offering Price(1) (2) |
|
|
Fee Rate |
|
|
Amount of Registration Fee |
|
|||||
Fees to be Paid |
|
Equity |
|
Common shares, $0.0001 par value per share(2) |
|
Rule 457(o) |
|
|
|
|
|
$ |
|
|
|
$ |
13,225,000 |
|
|
|
$0.0001102 |
|
|
|
$1,457.40 |
|
|
|
Equity |
|
Representative warrants(3) |
|
Rule 457(g) |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Fees to be Paid |
|
Equity |
|
Common shares issuable upon the exercise of the Representative’s warrants (4) |
|
Other |
|
|
|
|
|
$ |
|
|
|
$ |
826,562.50 |
|
|
|
$0.0001102 |
|
|
|
$91.09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Total Offering Amounts |
|
|
|
|
|
|
|
|
|
|
|
$ |
14,051,562.50 |
|
|
|
|
|
|
$ |
1,548.49 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Total Fees Previously Paid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Total Fee Offset |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Net Fee Due |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,548.49 |
|
(1) Includes shares of common stock of MAIA Biotechnology, Inc. (the “Company”), which the underwriters have the right to purchase to cover over-allotments. See “Underwriting.”
(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.
(3) No fee required pursuant to Rule 457(g).
(4) We have agreed to issue to the representative of the underwriters (the “Representative”), upon the closing of this offering, warrants to purchase up to an aggregate number of shares of our common stock (the “Representative’s Warrants”) in an aggregate equal to five percent (5%) of the aggregate number of shares of common stock to be issued and sold in this offering) (the “Representative’s Warrants”). The Representative’s Warrants are exercisable at a per share price equal to 125% of the public offering price per share of the shares of common stock sold in this offering. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the Representative’s Warrants is equal to 125% of $661,250 (which is equal to 5% of $13,225,000). See “Underwriting”.